SUMO2 and central nervous system cancer: Immunoprecipitation of endogenous NOP58 followed by immunoblotting with SUMO2 antibody in TAF15-knockdown cells and control cells indicated that endogenous NOP58 sumoylation was reduced after treating glioma cells with TAF15-targeted siRNAs (Fig. 6j and Supplementary Fig. 6k).